Please login to the form below

Not currently logged in


This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

BMS to test Vedanta’s bacterial therapy with Opdivo

BMS to test Vedanta’s bacterial therapy with Opdivo

The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in

Latest news

More from news
Approximately 11 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD).  . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)

  • Deal Watch June 2016 Deal Watch June 2016

    IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.

  • Deal Watch October 2015 Deal Watch October 2015

    Janssen's partnership with Canadian biotech enGene, facilitated through J&J Innovation, brings gene therapies for inflammatory bowel disease (IBD) and includes an undisclosed upfront payment and equity investment, R&D ... Research collaboration, option,

  • Pharma deals in June 2015 Pharma deals in June 2015

    the treatment of inflammatory bowel disease (IBD). ... 130. Lycera Corporation/ Celgene Corporation. Orally bioavailable RORgamma agonists for ex vivo use lead programme, LYC-30937  (oral gut-directed ATPase modulator for IBD, p1).

  • Getting real about patient support Getting real about patient support

    opposed to a series of acute episodes (such as in asthma, COPD or IBD).

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...